FilingReader Intelligence

Pharmaron reports strong Q1, director change, new award scheme

April 28, 2025 at 08:49 AM UTC•By FilingReader AI

Pharmaron Beijing (HKEX:3759) has released its first-quarter report for 2025, showcasing significant growth and outlining strategic initiatives. Revenue increased by 16.03% year-over-year to RMB3,098.8 million, and net profit attributable to owners of the parent surged 32.54% to RMB305.6 million. The company highlighted growth across laboratory services and CMC (small molecule CDMO) services and noted increased revenue from both top pharmaceutical clients and new customers.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

(1) RESIGNATION AND CESSATION OF OFFICE OF NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED BY-ELECTION OF NON-EXECUTIVE DIRECTOR OF THE THIRD SESSION OF THE BOARDApril 27, 2025 at 10:11 AM UTC

Supplementary Source Documents

(1) RESIGNATION AND CESSATION OF OFFICE OF NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED BY-ELECTION OF NON-EXECUTIVE DIRECTOR OF THE THIRD SESSION OF THE BOARDApril 27, 2025 at 10:21 AM UTC

Pharmaron Beijing

HKEX:3759•Hong Kong Exchange

RSS feed for Pharmaron Beijing

News Alerts

Get instant email alerts when Pharmaron Beijing publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →